Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Slides:

Advertisements

Similar presentations

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004 Tomohiko.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer Kyohei Masai, MD, Hiroyuki Sakurai,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection Takeshi Hanagiri, MD, PhD, Kenji Sugio,

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Kenji Suzuki, MD, Hisao.

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002 Noriyoshi Sawabata, MD,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of.

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Histological Scoring for Small Lung Adenocarcinomas 2 cm or Less in Diameter: A Reliable Prognostic Indicator Akiko Miyagi Maeshima, MD, Naobumi Tochigi,

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale.

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis

Carcinoma of the esophagus: Prognostic significance of histologic type

International Thymic Malignancies Interest Group: A Way Forward

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD, Etsuo.

Who should decide margin length in pulmonary excision of lung cancer?

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Visceral Pleural Invasion Classification in Non–Small-Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer:

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study Hiroyuki Sakurai, MD, Hisao Asamura, MD, Tomoyuki Goya, MD, Kenji Eguchi, MD, Yoichi Nakanishi, MD, Noriyoshi Sawabata, MD, Meinoshin Okumura, MD, Etsuo Miyaoka, PhD, Yoshitaka Fujii, MD Journal of Thoracic Oncology Volume 5, Issue 10, Pages 1594-1601 (October 2010) DOI: 10.1097/JTO.0b013e3181f1923b Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Distribution of histologic types between men and women. AD, adenocarcinoma; SQ, squamous cell carcinoma; LG, large cell carcinoma; AS, adenosquamous cell carcinoma. Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Overall survival curves based on gender. The 5-year survival rates of female (n = 4091) and male (n = 8008) patients are 75.6 and 57.9%, respectively. The difference in survival between the genders is significant (p = 0.0000). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival curves according to gender in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for adenocarcinoma is 61.9% for male patients and 77.7% for female patients. The difference in survival is significant (p = 0.0000). The 5-year survival rate for nonadenocarcinoma is 53.1% for male patients and 59.3% for female patients. The difference in survival is significant (p = 0.035). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Overall survival curves according to gender of pathologic stage I in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage I in adenocarcinoma is 78.6% for male patients and 90.0% for female patients (p = 0.0000). The 5-year survival rate for pathologic stage I in nonadenocarcinoma is 65.4% for male patients and 72.8% for female patients (p = 0.058). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Overall survival curves according to gender of pathologic stage II in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage II in adenocarcinoma is 47.5% for male patients and 57.5% for female patients (p = 0.018). The 5-year survival rate for pathologic stage II in nonadenocarcinoma is 53.5% for male patients and 61.9% for female patients (p = 0.28). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Disease-specific survival curves based on gender. The 5-year survival rates of female (n = 3890) and male (n = 7131) patients are 79.2 and 64.9%, respectively. The difference in survival between the genders is significant (p = 0.0000). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Disease-specific survival curves according to gender in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for adenocarcinoma is 67.5% for male patients and 80.8% for female patients. The difference in survival is significant (p = 0.0000). The 5-year survival rate for nonadenocarcinoma is 61.6% for male patients and 66.3% for female patients. The difference in survival is not significant (p = 0.17). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 8 Disease-specific survival curves according to gender for pathologic stage I in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage I in adenocarcinoma is 85.3% for male patients and 93.5% for female patients (p = 0.0000). The 5-year survival rate for pathologic stage I in nonadenocarcinoma is 77.1% for male patients and 81.9% for female patients (p = 0.14). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 9 Disease-specific survival curves according to gender for pathologic stage II in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage II in adenocarcinoma is 53.4% for male patients and 60.0% for female patients (p = 0.087). The 5-year survival rate for pathologic stage II in nonadenocarcinoma is 61.1% for male patients and 69.3% for female patients (p = 0.42). Journal of Thoracic Oncology 2010 5, 1594-1601DOI: (10.1097/JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions